SECsense Logo

Neumora Therapeutics 8-K Report: Key Developments on January 2, 2025

$NMRA
Form 8-K
Filed on: 2025-01-02
Source
Neumora Therapeutics 8-K Report: Key Developments on January 2, 2025

Based on the provided section of the financial report, here are the key pieces of information and insights extracted:

  1. Entity Information:
  • Company Name: Neumora Therapeutics, Inc.
  • Address: 490 Arsenal Way, Suite 200, Watertown, MA 02472
  • Phone Number: (857) 760-0900
  • CIK Code: 0001885522
  • SEC Central Index Key (CIK): This unique identifier is essential for tracking the company's filings with the SEC.
  1. Filing Type:
  • Form Type: 8-K
  • The 8-K form is used to report major events that shareholders should know about. This could include significant corporate changes, acquisitions, or other important developments.
  1. Reporting Period:
  • Report Date: January 2, 2025
  • The report is for a single day, indicating that it may pertain to an immediate event or announcement relevant to that date.
  1. Stock Information:
  • Common Stock Par Value: $0.0001 per share
  • Ticker Symbol: NMRA
  • Exchange: NASDAQ
  • This indicates that the company is publicly traded, and the stock is listed on the NASDAQ exchange.
  1. Financial Reporting Standards:
  • The report adheres to XBRL (eXtensible Business Reporting Language) guidelines, which is commonly used for financial reporting to enhance the transparency and accessibility of financial data.

Insights:

  • The filing of an 8-K suggests that Neumora Therapeutics may have had a significant event or announcement on January 2, 2025. Investors and stakeholders should look for additional details in this filing to understand the implications of this event.
  • As a biotechnology company (inferred from the name), Neumora Therapeutics may be involved in research and development activities that could impact its stock performance and investor interest.
  • The par value of the common stock being very low ($0.0001) may indicate a startup or early-stage company, which could be in a growth phase or seeking further investment.

This information will help stakeholders gauge the company's current status and any actions they may need to take in response to this report.